Behind Blue Eyes: New Eye Warnings for GLP-1s

Share

By Karen L. Kier, Pharmacist
On behalf of the ONU Healthwise Team 

Pete Townshend of the rock band The Who wrote the song “Behind Blue Eyes” as the band’s second single on the Who’s Next album. The song was released in October of 1971. The Who is considered one of the greatest rock bands of our time, and they were inducted into the Rock and Roll Hall of Fame in 1990.

On November 9, 2026, the U.S. Food and Drug Administration (FDA) announced that manufacturers of GLP-1 medications must add a warning to their prescribing information about a potential increased risk of a rare eye condition called non-arteritic anterior ischemic optic neuropathy, commonly known as NAION. The condition can cause sudden, painless vision loss in one eye and, in some cases, permanent blindness.

The Centers for Disease Control and Prevention (CDC) estimates that one out of every ten adults in the U.S. has a prescription for a GLP-1 to either control diabetes or weight loss or both. Between 2018 and September of 2025 in the U.S., slightly over 12 million prescriptions have been filled for GLP-1s.

Although Ozempic® and Mounjaro® are the more common names you hear, there is a long list of GLP-1s either as a solo mechanism of action or combined with other activity. The list of GLP- 1 medications include:

  • Semaglutide (Generic) Brand Names: Ozempic, Wegovy, Rybelsus, Oral Wegovy
  • Tirzepatide (Generic dual mechanism of action GIP/GLP-1 receptor agonist) Brand Names: Mounjaro, Zepbound
  • Orforglipron (Generic oral small-molecule GLP-1 receptor agonist) Brand Name: Foundayo
  • Liraglutide (Generic) Brand Names: Victoza, Saxenda
  • Dulaglutide (Generic) Brand Name: Trulicity
  • Exenatide / Exenatide extended-release (Generic) Brand Names: Byetta, Bydureon BCise

These medications have changed the treatment of obesity, diabetes, sleep apnea, and metabolic disorders. The new warning from the FDA is giving patients a reason to monitor their eye health and talk to their healthcare professionals.

What is NAION?
An analogy for explaining NAION is if you think of the optic nerve in the eye as an electrical cable connecting the eye to the brain. It carries the visual information allowing us to see. NAION occurs when blood flow to the front portion of the optic nerve is reduced, resulting in damage to the nerve fibers within the eye.

Sometimes referred to as an “eye stroke,” NAION typically affects one eye and can occur suddenly, often when a person wakes up in the morning. Unlike some other eye problems, it is generally painless. Symptoms may include sudden blurred vision, a dark or missing area in the visual field, difficulty seeing clearly in one eye, distorted colors or reduced central vision.

Risk factors for NAION include diabetes, high blood pressure, smoking, sleep apnea, anemia and kidney disease. These conditions are important because many people taking GLP-1 medications already have one or more of these underlying health concerns.

A 2024 study published in JAMA Ophthalmology made the connection between GLP-1 medications and NAION. Researchers examined medical records from 16,827 patients and found that individuals prescribed semaglutide had a higher risk of developing NAION compared with patients prescribed other medications for diabetes or obesity. Since this was an observational study design, the researchers emphasized that additional studies were needed to determine whether the medication actually caused the condition.

Based on the findings from this study, the FDA conducted a broader evaluation of the evidence. Its review included 126 randomized clinical trials involving more than 134,000 patients. The analysis identified 15 probable cases of NAION. Ten occurred among patients receiving GLP-1 medications, compared with five among patients receiving placebo or other treatments.

These numbers are meaningful. Although the findings suggest a potential increased risk, NAION remains very rare. The FDA has not established that these medications directly cause the condition, but felt a warning to healthcare professionals and the public was appropriate. The most important message is to not stop taking a prescribed medication without first talking with your healthcare professional. Patients should know the warning signs and seek immediate medical evaluation if they experience sudden, painless vision loss, blurred vision, blind spots or other unexpected changes in one eye.

People with diabetes should continue their regularly scheduled eye examinations. Patients on GLP-1s should continue with a yearly eye exam. According to the American Academy of Ophthalmology, additional eye examinations solely to screen for NAION before starting a GLP- 1 medication are not currently recommended.

The FDA’s announcement is a reminder that even highly effective medications deserve ongoing monitoring. GLP-1s offer benefits, including improved blood sugar control, weight management and reduced cardiovascular risk in certain populations.

See an eye healthcare professional to know what is behind your eyes!